Scienza e Tecnologia
Possible Breakthrough in Cardiovascular Disease Diagnostics for Europe and the European Union
According to the European Heart Network, each year cardiovascular disease causes and .
This is made possible with the product , a point-of-care assay to that can give results within , using a sample to test for the biomarkers, , and (eventually expanding to and ). It is in the advanced stages of R&D and progressing to . It will be submitted for FDA approval and then introduced to the market upon approval.
This product could be a game-changer, allowing patients to affordably screen for this potentially deadly condition , achieving results . This more efficiently guides patients to seek appropriate medical attention; those with prevailing heart conditions may also monitor their condition . In comparison to industry standards, it will be ; its peptide-coated cartridges will cost , while the quantitative electronic reader will cost . This is in to existing point-of-care devices also giving quantitative results for cardiac biomarkers, but at device costs of up to with cartridges ranging from .
The company's Scientific Advisory Board includes prominent leaders in this field, such as former Director General Indian Council of Medical Research (ICMR). The company has scheduled in five hospitals in India (including the renowned ), in the process of securing a large site in the US and five sites in Europe . It is also advanced discussions with and This is only one of many pipeline products made possible by its patented method of peptide-design. The immediate pipeline includes assays for
It specializes in using a peptide-based approach to disrupt and democratize the diagnostics industry with affordable devices, able to provide lab-quality results in a fraction of the time and at a fraction of the cost. In line with its motto, "Convergence of Science" that integrates elements of life sciences, nanotechnology, electronics, and AI/machine learning in its products. The company is aware of the cost-inefficiencies of existing diagnostic solutions, therefore, the mission is to develop accurate, efficient and affordable diagnostic solutions to prevalent global health issues.
Learn more about TruHeart™: https://neuomepeptides.com/truheart/
Photo - https://mma.prnewswire.com/media/1968350/TruHeart_04.jpg
Logo - https://mma.prnewswire.com/media/1968342/NeuomePeptides_newLogo__1_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/possible-breakthrough-in-cardiovascular-disease-diagnostics-for-europe-and-the-european-union-301705046.html